<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386553</url>
  </required_header>
  <id_info>
    <org_study_id>232SM201</org_study_id>
    <secondary_id>2014-002098-12</secondary_id>
    <nct_id>NCT02386553</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy</brief_title>
  <acronym>NURTURE</acronym>
  <official_title>An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen
      administered intrathecally in preventing or delaying the need for respiratory intervention or
      death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA).
      Secondary objectives of this study are to examine the effects of Nusinersen in infants with
      genetically diagnosed and presymptomatic SMA.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 20, 2015</start_date>
  <completion_date type="Anticipated">January 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to death or respiratory intervention</measure>
    <time_frame>Up to Day 1820</time_frame>
    <description>The time will be the age of the participant at the first occurrence of either a respiratory intervention or death. Respiratory intervention is defined as invasive or noninvasive ventilation for ≥6 hours/day continuously for 7 or more days OR tracheostomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).</measure>
    <time_frame>At 13 and 24 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants alive</measure>
    <time_frame>At 13 months, and 2, 3, 4 and 5 years of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)</measure>
    <time_frame>At 13 and 24 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria</measure>
    <time_frame>At 13 and 24 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in weight for age/length</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in head circumference</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in chest circumference ratio</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in head to chest circumference ratio</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in arm circumference ratio</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and/or serious adverse events (SAEs)</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in clinical laboratory parameters</measure>
    <time_frame>Up to Day 1820</time_frame>
    <description>Assessed by the following laboratory tests: Hematology: red blood cells, hemoglobin, hematocrit, platelets, white blood cells, white blood cell differential, Blood chemistry: total protein, albumin, creatinine, cystatin C, creatine phosphokinase, blood urea nitrogen, total bilirubin (direct and indirect), alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, glucose, calcium, phosphorous, chloride, sodium, potassium. Urinalysis: specific gravity, pH, protein, glucose, ketones, bilirubin, red blood cells, white blood cells, epithelial cells, bacteria, casts, crystals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in electrocardiograms (ECGs)</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in vital signs</measure>
    <time_frame>Up to Day 1820</time_frame>
    <description>Vital sign will be assessed by: temperature, pulse rate, resting systolic and diastolic blood pressure, and respiratory rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in neurological examinations</measure>
    <time_frame>Up to Day 1820</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.</measure>
    <time_frame>Up to Day 1730</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Nusinersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nusinersen administered as an intrathecal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nusinersen</intervention_name>
    <description>Solution for intrathecal injection</description>
    <arm_group_label>Nusinersen</arm_group_label>
    <other_name>ISIS 396443</other_name>
    <other_name>BIIB058</other_name>
    <other_name>ISIS SMNRx</other_name>
    <other_name>Spinraza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Age ≤ 6 weeks at first dose

          -  Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound
             heterozygous mutation.

          -  Genetic documentation of 2 or 3 copies of survival motor neuron 2 (SMN2).

          -  Ulnar compound muscle action potential (CMAP) ≥ 1 mV at Baseline.

          -  Gestational age of 37 to 42 weeks for singleton births; gestational age of 34 to 42
             weeks for twins.

          -  Meet additional study related criteria.

        Key Exclusion Criteria:

          -  Hypoxemia (oxygen saturation &lt;96% awake or asleep without any supplemental oxygen or
             respiratory support).

          -  Any clinical signs or symptoms at Screening or immediately prior to the first dosing
             (Day 1) that are, in the opinion of the Investigator, strongly suggestive of SMA.

          -  Clinically significant abnormalities in hematology or clinical chemistry parameters.

          -  Treatment with an investigational drug given for the treatment of SMA biological
             agent, or device. Any history of gene therapy, prior antisense oligonucleotide (ASO)
             treatment, or cell transplantation.

          -  Meet additional study related criteria.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center, The SMA Clinical Research Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital- Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neuropediatrics and Muscle Disorders Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu' Children's Research Hospital</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Serena Onlus - Centro Clinico Nemo</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamad General Hospital</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>806</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <state>Sihhiye</state>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Qatar</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Israel</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NURTURE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

